Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VMX-C001 in Healthy Subjects and in Combination With a DOAC in Healthy Older Subjects
NCT06372483Phase 1Completed
- Sponsor
- VarmX
- Start
- Feb 2024
- Primary completion
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VMX-C001 in coagulation disorder (10 cohorts), sponsored by VarmX. Primary endpoints: Incidence of Treatment-Emergent Adverse Events, Maximum Plasma Concentration and 21 more. Started Feb 2024; status: completed.
02
Drugs
VMX-C001
03
Conditions
coagulation disorder
Beyond the preview
Go deeper on NCT06372483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06372483.